NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Cardio-Oncology
Nathalie I BouwerEric Boersma

Abstract

Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is most widely used, is unable to detect subclinical cardiac changes. The use of N-terminal pro-brain natriuretic peptide (NT-proBNP), a serum biomarker of myocardial stress, might improve timely diagnosis. This prospective, single-center, cohort study included patients with HER2-positive breast cancer who started trastuzumab therapy. Echocardiography was scheduled at regular intervals every 3 months during one year follow-up for cardiac function monitoring. For research purposes, NT-proBNP was determined at the same time points. Trastuzumab-induced cardiotoxicity (TIC) was the primary study endpoint, defined as a left ventricular ejection fraction (LVEF) < 45%, and/or an absolute decline in LVEF > 10% since inclusion, and/or the incidence of a clinical cardiac event. A total of 135 patients were enrolled between April 2008 and June 2016, with a median age of 54 years (IQR: 47-61). By three-dimensional echocardiography (3DE), the median LVEF at baseline was 62% (IQR: 58-65). At a median of 6 months (IQR: 5-11), 45 patients (33...Continue Reading

References

Feb 22, 2005·Nuclear Medicine Communications·John V SkrypniukDavid R Whalley
Jun 11, 2005·Journal of Cardiac Failure·Christian Hall
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S EwerDaniel J Lenihan
Jan 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S Ewer, Daniel J Lenihan
Jun 21, 2008·Radiology·Fred A MettlerMahadevappa Mahesh
Mar 5, 2011·The American Journal of Cardiology·Heloisa SawayaMarielle Scherrer-Crosbie
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick G MorrisChau T Dang
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory T ArmstrongScott D Flamm
Sep 6, 2012·Journal of the National Cancer Institute·Erin J Aiello BowlesUNKNOWN Pharmacovigilance Study Team
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CuriglianoUNKNOWN ESMO Guidelines Working Group
Nov 20, 2012·Journal of the American College of Cardiology·Jersey ChenCary P Gross
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon H GiordanoUNKNOWN American Society of Clinical Oncology
Aug 20, 2016·JAMA Cardiology·Edward T H Yeh, Hui-Ming Chang
Nov 4, 2017·Journal of the American College of Cardiology·Laura C van VarkUNKNOWN TRIUMPH Investigators

❮ Previous
Next ❯

Citations

May 4, 2020·The Breast : Official Journal of the European Society of Mastology·Nathalie I BouwerMark-David Levin

❮ Previous
Next ❯

Methods Mentioned

BETA
blood

Software Mentioned

nlme
SPSS
JM
R
Echopac

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.